◼ Archived
Health
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
Novo
32 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
Probing the many benefits of GLP-1 receptor agonists
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
◼ Archived
Business
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
◼ Archived
Business
Novo defends diversification push as CEO eyes deals beyond obesity
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy maker Novo shares slump as management grilled on pricing, M&A
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
◼ Archived
Business
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk signs a licensing agreement worth up to $1.4 billion with Orbis Medicines to develop oral therapeutics.
◼ Archived
Business
Novo Nordisk Will Use Anthropic’s Claude for Drug Research
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
No more Nordisk as Novo goes it alone amid rebranding push
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo Nordisk Slims Down Name to Novo
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk Stock Bounces Back After Surprise Earnings Report
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo outlook hike falls flat as Wegovy pill sales fail to impress
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk rocked by late-stage cardiovascular drug failure
Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.
◼ Archived
Business
🔮 fades ✓
Novo drug trial fail deals setback to bid to expand beyond obesity
Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
◼ Archived
Health
🔮 fades
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
◼ Archived
Health
🔮 fades
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from a phase 1/2 human clinical trial.
◼ Archived
Business
🔮 fades
The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.